The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
Abstract
Background Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes. Methods In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m 2 , or at least 27 kg/m 2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-calorie diet and increased physical activity. Time to diabetes onset by 160 weeks was the primary outcome, evaluated in all randomised treated individuals with at least one post-baseline assessment. The trial was conducted at 191 clinical research sites in 27 countries and is registered with ClinicalTrials.gov, number NCT01272219. Findings The study ran between June 1, 2011, and March 2, 2015. We randomly assigned 2254 patients to receive liraglutide (n=1505) or placebo (n=749). 1128 (50%) participants completed the study up to week 160, after withdrawal of 714 (47%) participants in the liraglutide group and 412 (55%) participants in the placebo group. By week 160, 26 (2%) of 1472 individuals in the liraglutide group versus 46 (6%) of 738 in the placebo group were diagnosed with diabetes while on treatme…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For patients with BMI greater than 30 kg/m2 (or 27–30 kg/m2 with obesity-related comorbid conditions), obesity pharmacotherapy leads to as much as 15% weight loss in responders, with weight loss being maintained in several studies for several years90–92.”
From Maintenance of Lost Weight and Long-Term Management of Obesity (2018) · cites this paper as [91]
In the citing paper
“The translation of the structured lifestyle intervention used in the Diabetes Prevention Program to community-based programs, commercial programs, and programs using remote technologies have achieved less weight loss than observed in the Diabetes Prevention Program trial itself.861–869”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [868]
In the citing paper
“prediabetes to type 2 diabetes by 66-93% compared with placebo.65,75,76”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [75]
In the citing paper
“The longest controlled trials of GLP-1 receptor agonist usage are 3–4 years,12,13 and the long-term effects beyond this time are not well-described.”
In the citing paper
“In a 3-year trial in 2254 participants with obesity and prediabetes, liraglutide 3.0 mg improved CV risk factors including blood pressure and lipids [12].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [12]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Banks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., Tsiotos, G. G., & Vege, S. S. (2013) · Gut · doi:10.1136/gutjnl-2012-302779 · Cited by 7,187
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s062 · Cited by 5,491
Prediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Self-citationPrevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012
Menke, A., Casagrande, S., Geiss, L., & Cowie, C. C. (2015) · JAMA · doi:10.1001/jama.2015.10029 · Cited by 2,362
Cited by
Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Ahmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01655-5 · Cited by 1,120
Blüher, M. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa004 · Cited by 1,090
Self-citationLean, M. E. J., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30068-3 · Cited by 1,017
Self-citation
Metadata
- Authors
- le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., Pi-Sunyer, X., Hamann, A., Barakat, A., Blüher, M., Linn, T., Mölle, A., Segner, A., Stübler, P., Tosch-Sisting, R., Pacini, F., Santini, F., Marchesini, G., Rotella, C. M., Invitti, C., Vettor, R., Buscemi, S., Raya, P. M., Freijoo, F. C., de Barbará, R. G., Carraro, R., Bobillo, E. R., de la Cuesta, C., Farsang, C., Csaszar, A., Zahorska-Markiewicz, B., Pupek-Musialik, D., Franek, E., Ostrowska, L., Olszanecka-Glinianowicz, M., Lalic, N., Micic, D., Ludvik, B., Paulweber, B., Prager, R., Scheen, A., Van Gaal, L., Astrup, A. V., Hermansen, K., Madsbad, S., Rissanen, A., Nieminen, S., Savolainen, M., Krempf, M., Romon, M., Laville, M., Marre, M., Mira, R., Finucane, F., Veenendaal, A., van Berkum, F., Johannsson-Vidarsdóttir, S., Van de Walle, V., Meesters, E., Hjelmesæth, J., Klemsdal, T. O., Kulseng, B., Bach-Kliegel, B., Laederach, K., Villiger, L., Golay, A., Bilz, S., Sathyapalan, T., Bain, S., Kumar, S., Le Roux, C. W., Lean, M. E. J., McGowan, B., Rehman, T., Wilding, J., Wittert, G., Caterson, I., Proietto, J., Prins, J., Neto, B. G., Gross, J. L., Chacra, A. R., Halpern, A., de Almeida Suplicy, H., Chow, F. C. C., Thacker, H. P., Chadha, M., Chandalia, H., Unnikrishnan, A., Kalra, S., Deshpande, N., Shunmugavelu, M., Deshmukh, V. C., Maislos, M., Lieberman, G. S., Shimon, I., Stern, N., Nabriski, D., Karnieli, E., Shehadeh, N., Gonzalez-Galvez, G., del Rosario Arechavaleta-Granell, M., Ortiz, R. M. V., Franco, G. M., Gurieva, I., Suplotova, L. A., Troshina, E., Ruyatkina, L. A., Voychik, E. A., Martsevich, S., Startseva, M. A., Seeber, M. E., Badat, A., Ellis, G., Altuntas, Y., Guler, S., Ulgen, E., Delibasi, T., Chetty, T., Hart, R., Janzen, J., Labonte, I., Lau, D., Liutkus, J., O'Keefe, D., Padwal, R., Ransom, T. P. P., Tytus, R., Weisnagel, S. J., Adler, J., Aqua, K., Aronoff, S. L., Bedel, G. W., Blevins, T. C., Blumenau, J., Brockmyre, A. P., Call, R. S., Canadas, R., Chaykin, L. B., Cohen, K., Conrow, J. K., Davis, M. G., Downey, H. J., Drosman, S. R., Duckor, S., Farmer, H. F., Farrell, J., Fehnel, S., Finneran, M. P., Forbes, R., Forker, A., Fredrick, M., Fujioka, K., Geller, S. A., Gill, S., Glaser, L., Greco, S. N., Greenway, F. L., Harper, W., Herman, L., Hoekstra, J., Ingebretsen, R., Ison, R., Jain, R. K., Kaplan, R., Kaster, S. R., Haase, G. A., Kerzner, B., Kirstein, J. L., Koltun, W., Krieger, D. R., Lewis, C. E., Madder, R., Marple, R. N., McDermott, E. J., Mello, C. J., Miller, A. B., Mullen, J., Nardandrea, J., O'Neil, P., Pi-Sunyer, F. X., Pucillo, R. M., Rhee, C., Redrick, S., Pardini, A., Rothman, J., Rubino, D. M., Sellers, G., Smith, T., Byars, W. D., Soufer, J., Sussman, A. M., Patrick, K., Schramm, E. L., Van Cleeff, M., Berg, S. R., Wyatt, H. R., & Simon, J. A.
- Affiliations
- University of Copenhagen (DK)
- Pennington Biomedical Research Center (US)
- University of Calgary (CA)
- University of Liverpool (GB)
- Novo Nordisk (Denmark) (DK)
- Columbia University (US)
- Institut National de la Recherche Agronomique (FR)
- Mexican Social Security Institute (MX)
- ORCID
- Skjøth, Trine V
- Manning, Linda Shapiro
- Blüher, Matthias
- Linn, Thomas
- Pacini, Furio
- Santini, Ferruccio
- Marchesini, Giulio
- Rotella, Carlo Maria
- Invitti, Cecilia
- Vettor, Roberto
- Buscemi, Silvio
- Carraro, Raffaele
- Franek, Edward
- Ostrowska, Lucyna
- Lalic, Nebojsa
- Ludvik, Bernhard
- Paulweber, Bernhard
- Scheen, André
- Hermansen, Kjeld
- Madsbad, Sten
- Savolainen, Markku
- Krempf, Michel
- Laville, Martine
- Marre, Michel
- Finucane, Francis
- Klemsdal, Tor Ole
- Kulseng, Bård
- Laederach, Kurt
- Golay, Alain
- Bilz, Stefan
- Sathyapalan, Thozhukat
- Bain, Stephen
- Lean, Michael E.J.
- McGowan, Barbara
- Wittert, Gary
- Gross, Jorge Luiz
- Thacker, Hemant P
- Kalra, Sanjay
- Deshpande, Neeta
- Deshmukh, Vaishali Chetan
- Shimon, Ilan
- Stern, Naftali
- Karnieli, Eddy
- Shehadeh, Naim
- Troshina, Ekaterina
- Martsevich, Sergey
- Ellis, Graham
- Padwal, Raj
- Tytus, Richard
- Weisnagel, Stanley John
- Aqua, Keith
- Blevins, Thomas Craig
- Davis, Matthew G
- Geller, Steven Andrew
- Kirstein, Judith Lee
- Lewis, Cora Elizabeth
- Mello, Curtis John
- O'Neil, Patrick
- Rothman, Jeffrey
- Rubino, Domenica Marie
- Smith, Timothy
- Wyatt, Holly Roxanna
- Simon, James Alan
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 389
- Issue
- 10077
- Pages
- 1399-1409
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2590664415
- Cited by
- 850
- References
- 33
- Citations by year
- 2026: 82 · 2025: 114 · 2024: 124 · 2023: 90 · 2022: 86 · 2021: 108 · 2020: 70 · 2019: 65 · 2018: 59 · 2017: 47
- FWCI
- 52.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- liraglutide, type 2 diabetes prevention, prediabetes, weight management, GLP-1 receptor agonists, hypocaloric diet, physical activity, body weight, glucose metabolism, diabetes prevention, long-term follow-up, subcutaneous administration
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Obesity, Placebos, Prediabetic State, Weight Loss, Body Mass Index, Treatment Outcome, Risk Reduction Behavior, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. https://app.cochat.ai/papers/10.1016/s0140-6736(17)30069-7
- The paper
- le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., Pi-Sunyer, X., Hamann, A., Barakat, A., Blüher, M., Linn, T., Mölle, A., Segner, A., Stübler, P., Tosch-Sisting, R., . . . Simon, J. A. (2017). 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. The Lancet. https://doi.org/10.1016/s0140-6736(17)30069-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.